Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective

Appl Health Econ Health Policy. 2014 Aug;12(4):409-20. doi: 10.1007/s40258-014-0108-7.


Background: With limited healthcare resources available, cost-effective provision of dialysis to patients with end-stage renal disease (ESRD) is important.

Objectives: To assess the cost-effectiveness of varying levels of peritoneal dialysis (PD) use versus current practice among incident ESRD patients requiring dialysis.

Methods: A Markov model was developed to investigate the cost-effectiveness of increasing uptake of PD to 39 and 50 % versus current practice of 22 % PD from a UK National Health Service perspective for the year of 2013-2014. A scenario with 5 % PD was also considered. Sensitivity analyses were performed.

Results: Five- and 10-year discounted total costs and quality-adjusted life years (QALYs) per patient for the current scenario (22 % PD) were £96,307 and 2.104, and £133,339 and 3.301, respectively. Use of PD in 39 % of patients resulted in 5- and 10-year total per-patient cost savings of £3,180 and £4,102 versus current usage alongside total per-patient QALY increases of 0.017 and 0.020. Use of PD in 50 % of patients resulted in 5- and 10-year per-patient cost savings of £5,238 and £6,758 versus current usage alongside per-patient QALY increases of 0.029 and 0.033. Thus, increasing use of PD was associated with marginally better outcomes and lower costs. Cost savings were driven by lower treatment costs and reduced transport requirements for PD versus haemodialysis. Reducing PD use was associated with higher costs and a small reduction in QALYs.

Conclusions: These findings suggest increasing PD use among incident dialysis patients would be cost-effective, associated with reduced costs and potential modest improvements in quality of life.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ambulatory Care Facilities*
  • Cost-Benefit Analysis*
  • Health Expenditures*
  • Humans
  • Kidney Failure, Chronic / economics
  • Kidney Failure, Chronic / therapy*
  • Markov Chains
  • Models, Econometric
  • Peritoneal Dialysis / economics*
  • Quality of Life
  • Quality-Adjusted Life Years
  • State Medicine
  • United Kingdom